309 related articles for article (PubMed ID: 37467930)
21. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.
Herbst RS; Wu YL; John T; Grohe C; Majem M; Wang J; Kato T; Goldman JW; Laktionov K; Kim SW; Yu CJ; Vu HV; Lu S; Lee KY; Mukhametshina G; Akewanlop C; de Marinis F; Bonanno L; Domine M; Shepherd FA; Urban D; Huang X; Bolanos A; Stachowiak M; Tsuboi M
J Clin Oncol; 2023 Apr; 41(10):1830-1840. PubMed ID: 36720083
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1.
Escudero-Vilaplana V; Collado-Borrell R; De Castro J; Insa A; Martínez A; Fernández E; Sullivan I; Flores A; Arrabal N; Carcedo D; Manzaneque A
J Med Econ; 2023; 26(1):445-453. PubMed ID: 36883193
[TBL] [Abstract][Full Text] [Related]
23. First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.
Özgüroğlu M; Kilickap S; Sezer A; Gümüş M; Bondarenko I; Gogishvili M; Nechaeva M; Schenker M; Cicin I; Ho GF; Kulyaba Y; Zyuhal K; Scheusan RI; Garassino MC; He X; Kaul M; Okoye E; Li Y; Li S; Pouliot JF; Seebach F; Lowy I; Gullo G; Rietschel P
Lancet Oncol; 2023 Sep; 24(9):989-1001. PubMed ID: 37591293
[TBL] [Abstract][Full Text] [Related]
24. Results from the IMpower132 China cohort: Atezolizumab plus platinum-based chemotherapy in advanced non-small cell lung cancer.
Lu S; Fang J; Wang Z; Fan Y; Liu Y; He J; Zhou J; Hu J; Xia J; Liu W; Shi J; Yi J; Cao L
Cancer Med; 2023 Feb; 12(3):2666-2676. PubMed ID: 36052772
[TBL] [Abstract][Full Text] [Related]
25. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M
Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441
[TBL] [Abstract][Full Text] [Related]
26. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
Herbst RS; Giaccone G; de Marinis F; Reinmuth N; Vergnenegre A; Barrios CH; Morise M; Felip E; Andric Z; Geater S; Özgüroğlu M; Zou W; Sandler A; Enquist I; Komatsubara K; Deng Y; Kuriki H; Wen X; McCleland M; Mocci S; Jassem J; Spigel DR
N Engl J Med; 2020 Oct; 383(14):1328-1339. PubMed ID: 32997907
[TBL] [Abstract][Full Text] [Related]
27. Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.
Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Wei YC; Liu YY; Chen C; Cheng Y; Yin R; Yang F; Ren SX; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yang JJ; Yan HH; Yang XN; Liu SY; Zhou Q; Wu YL
J Clin Oncol; 2021 Mar; 39(7):713-722. PubMed ID: 33332190
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
Shu CA; Gainor JF; Awad MM; Chiuzan C; Grigg CM; Pabani A; Garofano RF; Stoopler MB; Cheng SK; White A; Lanuti M; D'Ovidio F; Bacchetta M; Sonett JR; Saqi A; Rizvi NA
Lancet Oncol; 2020 Jun; 21(6):786-795. PubMed ID: 32386568
[TBL] [Abstract][Full Text] [Related]
29. Atezolizumab in Japanese Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study.
Hida T; Kaji R; Satouchi M; Ikeda N; Horiike A; Nokihara H; Seto T; Kawakami T; Nakagawa S; Kubo T
Clin Lung Cancer; 2018 Jul; 19(4):e405-e415. PubMed ID: 29525239
[TBL] [Abstract][Full Text] [Related]
30. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
Miles D; Gligorov J; André F; Cameron D; Schneeweiss A; Barrios C; Xu B; Wardley A; Kaen D; Andrade L; Semiglazov V; Reinisch M; Patel S; Patre M; Morales L; Patel SL; Kaul M; Barata T; O'Shaughnessy J;
Ann Oncol; 2021 Aug; 32(8):994-1004. PubMed ID: 34219000
[TBL] [Abstract][Full Text] [Related]
31. International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer.
Novello S; Torri V; Grohe C; Kurz S; Serke M; Wehler T; Meyer A; Ladage D; Geissler M; Colantonio I; Cauchi C; Stoelben E; Ceribelli A; Kropf-Sanchen C; Valmadre G; Borra G; Schena M; Morabito A; Santo A; Gregorc V; Chiari R; Reck M; Schmid-Bindert G; Folprecht G; Griesinger F; Follador A; Pedrazzoli P; Bearz A; Caffo O; Dickgreber NJ; Irtelli L; Wiest G; Monica V; Porcu L; Manegold C; Scagliotti GV
Ann Oncol; 2022 Jan; 33(1):57-66. PubMed ID: 34624497
[TBL] [Abstract][Full Text] [Related]
32. Comparison of SP263 and 22C3 pharmDx assays to test programmed death ligand-1 (PD-L1) expression in surgically resected non-small cell lung cancer.
Shigeta N; Murakami S; Yokose T; Isaka T; Shinada K; Nagashima T; Adachi H; Shigefuku S; Murakami K; Miura J; Kikunishi N; Watabe K; Saito H; Ito H
Thorac Cancer; 2024 Jun; 15(17):1343-1349. PubMed ID: 38698758
[TBL] [Abstract][Full Text] [Related]
33. Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma.
Motzer RJ; Powles T; Atkins MB; Escudier B; McDermott DF; Alekseev BY; Lee JL; Suarez C; Stroyakovskiy D; De Giorgi U; Donskov F; Mellado B; Banchereau R; Hamidi H; Khan O; Craine V; Huseni M; Flinn N; Dubey S; Rini BI
JAMA Oncol; 2022 Feb; 8(2):275-280. PubMed ID: 34940781
[TBL] [Abstract][Full Text] [Related]
34. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Mok TSK; Wu YL; Kudaba I; Kowalski DM; Cho BC; Turna HZ; Castro G; Srimuninnimit V; Laktionov KK; Bondarenko I; Kubota K; Lubiniecki GM; Zhang J; Kush D; Lopes G;
Lancet; 2019 May; 393(10183):1819-1830. PubMed ID: 30955977
[TBL] [Abstract][Full Text] [Related]
35. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).
Peters S; Gettinger S; Johnson ML; Jänne PA; Garassino MC; Christoph D; Toh CK; Rizvi NA; Chaft JE; Carcereny Costa E; Patel JD; Chow LQM; Koczywas M; Ho C; Früh M; van den Heuvel M; Rothenstein J; Reck M; Paz-Ares L; Shepherd FA; Kurata T; Li Z; Qiu J; Kowanetz M; Mocci S; Shankar G; Sandler A; Felip E
J Clin Oncol; 2017 Aug; 35(24):2781-2789. PubMed ID: 28609226
[TBL] [Abstract][Full Text] [Related]
36. FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC.
Spigel DR; Chaft JE; Gettinger S; Chao BH; Dirix L; Schmid P; Chow LQM; Hicks RJ; Leon L; Fredrickson J; Kowanetz M; Sandler A; Funke R; Rizvi NA
J Thorac Oncol; 2018 Nov; 13(11):1733-1742. PubMed ID: 29775807
[TBL] [Abstract][Full Text] [Related]
37. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
[TBL] [Abstract][Full Text] [Related]
38. Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial.
Kurtz JE; Pujade-Lauraine E; Oaknin A; Belin L; Leitner K; Cibula D; Denys H; Rosengarten O; Rodrigues M; de Gregorio N; Martinez García J; Petru E; Kocián R; Vergote I; Pautier P; Schmalfeldt B; Gaba L; Polterauer S; Mouret Reynier MA; Sehouli J; Churruca C; Selle F; Joly F; D'Hondt V; Bultot-Boissier É; Lebreton C; Lotz JP; Largillier R; Heudel PE; Heitz F;
J Clin Oncol; 2023 Oct; 41(30):4768-4778. PubMed ID: 37643382
[TBL] [Abstract][Full Text] [Related]
39. Alectinib in Resected
Wu YL; Dziadziuszko R; Ahn JS; Barlesi F; Nishio M; Lee DH; Lee JS; Zhong W; Horinouchi H; Mao W; Hochmair M; de Marinis F; Migliorino MR; Bondarenko I; Lu S; Wang Q; Ochi Lohmann T; Xu T; Cardona A; Ruf T; Noe J; Solomon BJ;
N Engl J Med; 2024 Apr; 390(14):1265-1276. PubMed ID: 38598794
[TBL] [Abstract][Full Text] [Related]
40. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial.
Jotte R; Cappuzzo F; Vynnychenko I; Stroyakovskiy D; Rodríguez-Abreu D; Hussein M; Soo R; Conter HJ; Kozuki T; Huang KC; Graupner V; Sun SW; Hoang T; Jessop H; McCleland M; Ballinger M; Sandler A; Socinski MA
J Thorac Oncol; 2020 Aug; 15(8):1351-1360. PubMed ID: 32302702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
